• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    NexGel Inc filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    4/24/26 5:15:16 PM ET
    $NXGL
    Medical/Dental Instruments
    Health Care
    Get the next $NXGL alert in real time by email
    false 0001468929 0001468929 2026-04-22 2026-04-22 0001468929 NXGL:CommonStockParValue0.001Member 2026-04-22 2026-04-22 0001468929 NXGL:WarrantsToPurchaseCommonStockMember 2026-04-22 2026-04-22 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): April 22, 2026

     

    NEXGEL, INC.
    (Exact name of registrant as specified in its charter)

     

    Delaware   001-41173   26-4042544
    (State or other jurisdiction  

    (Commission

      (IRS Employer
    of incorporation)   File Number)   Identification No.)

     

    2150 Cabot Boulevard West, Suite B

    Langhorne, Pennsylvania

      19047
    (Address of principal executive offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: (215) 702-8550

     

    (Former name or former address, if changed since last report)

    Not Applicable

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.001   NXGL   The Nasdaq Capital Market LLC
    Warrants to Purchase Common Stock   NXGLW   The Nasdaq Capital Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

     

    On April 22, 2026, NexGel, Inc. (the “Company”) received a deficiency letter from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Nasdaq deficiency letter has no immediate effect on the listing of the Company’s common stock, and its common stock will continue to trade on The Nasdaq Capital Market under the symbol “NXGL” at this time.

     

    In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been given 180 calendar days, or until October 19, 2026, to regain compliance with the Minimum Bid Price Requirement. If at any time before October 19, 2026, the bid price of the Company’s common stock closes at $1.00 per share or more for a minimum of 10 consecutive business days, the Staff will provide written confirmation that the Company has achieved compliance.

     

    If the Company does not regain compliance with the Minimum Bid Price Requirement by October 19, 2026, the Company may be afforded a second 180 calendar day period to regain compliance. To qualify, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, except for the Minimum Bid Price Requirement. In addition, the Company would be required to notify Nasdaq of its intent to cure the deficiency during the second compliance period, by effecting a reverse stock split if necessary. If the Company does not regain compliance with the Minimum Bid Price Requirement by the end of the compliance period (or the second compliance period, if applicable), the Company’s common stock will become subject to delisting. In the event that the Company receives notice that its common stock is being delisted, the Nasdaq listing rules permit the Company to appeal a delisting determination by the Staff to a hearings panel.

     

    The Company intends to monitor the closing bid price of its common stock and may, if appropriate, consider available options to regain compliance with the Minimum Bid Price Requirement, including initiating a reverse stock split. However, there can be no assurance that the Company will be able to regain compliance with the Minimum Bid Price Requirement or will otherwise be in compliance with other Nasdaq Listing Rules.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: April 24, 2026    
           
        NEXGEL, INC.
           
        By: /s/ Adam Levy
          Adam Levy
          Chief Executive Officer

     

     

     

    Get the next $NXGL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NXGL

    DatePrice TargetRatingAnalyst
    2/25/2022$6.00Buy
    Maxim Group
    More analyst ratings

    $NXGL
    SEC Filings

    View All

    SEC Form PRE 14A filed by NexGel Inc

    PRE 14A - NEXGEL, INC. (0001468929) (Filer)

    5/29/26 5:30:08 PM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by NexGel Inc

    10-Q - NEXGEL, INC. (0001468929) (Filer)

    5/14/26 5:29:01 PM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    NexGel Inc filed SEC Form 8-K: Financial Statements and Exhibits

    8-K - NEXGEL, INC. (0001468929) (Filer)

    5/12/26 4:30:25 PM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    $NXGL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NEXGEL to Present at Planet MicroCap Conference Las Vegas on June 16th –18th

    LANGHORNE, Pa., June 04, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced that Adam Levy, Chief Executive Officer, will present at the Planet MicroCap Conference on June 16 – 18, 2026, in Las Vegas, NV. Planet MicroCap Las Vegas 2026Dates: June 16-18, 2026Location: Bellagio Hotel & Casino, Las Vegas, NVBooth: #517Presentation Day and Time: Wednesday, June 17, 2026, at 1:30 P.M. PTPresentation Location: Track 3 - Da Vinci 3Webcast: https://ir.nexgel.com/news-events/events-presentat

    6/4/26 9:00:00 AM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    NEXGEL Reports Positive Data from Randomized Single-Center IRB Study to Evaluate the Effectiveness and Safety of a Hydrogel Laser Treatment Patch in Laser Hair Removal with a 95.6% Reduction in Plume Concentration

    The study concluded that NEXGEL's hydrogel patch significantly reduced laser plume generation and exposure during laser hair removal and the patch was associated with greater hair reduction and reduced pain compared to the control The study was published in Lasers in Surgery and Medicine, 2026 LANGHORNE, Pa., May 19, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced positive data from the randomized, 30-patient, single-center Institutional Review Board (IRB) clinical study, funded

    5/19/26 9:00:00 AM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    NEXGEL Appoints Dave Hazard as Vice President of Sales for BIONX Surgical

    Appointment Supports Commercialization of Newly Launched BIONX Surgical Division, Formed Through Transformative Acquisition Expected to Significantly Scale Revenue LANGHORNE, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the appointment of Dave Hazard as Vice President of Sales for BIONX Surgical, a division of NEXGEL. Mr. Hazard brings more than 13 years of sales leadership across orthopedics, spine, and biologics, and joins BIONX Surgical at a

    5/13/26 8:30:00 AM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    $NXGL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Levy Adam R. sold $1,172 worth of shares (2,000 units at $0.59), decreasing direct ownership by 0.58% to 342,692 units (SEC Form 4)

    4 - NEXGEL, INC. (0001468929) (Issuer)

    6/3/26 6:53:31 PM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Levy Adam R. sold $7,834 worth of shares (13,000 units at $0.60), decreasing direct ownership by 4% to 344,692 units (SEC Form 4)

    4 - NEXGEL, INC. (0001468929) (Issuer)

    5/29/26 8:03:52 PM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Henry Scott Robert

    4 - NEXGEL, INC. (0001468929) (Issuer)

    5/18/26 8:04:53 PM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    $NXGL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Levy Adam R. bought $9,999 worth of shares (3,636 units at $2.75), increasing direct ownership by 1% to 333,196 units (SEC Form 4)

    4 - NEXGEL, INC. (0001468929) (Issuer)

    11/22/24 4:54:14 PM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    Director Zeldis Jerome B bought $9,999 worth of shares (3,636 units at $2.75), increasing direct ownership by 4% to 106,664 units (SEC Form 4)

    4 - NEXGEL, INC. (0001468929) (Issuer)

    11/22/24 4:54:12 PM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    Director Stein John Nachum gifted 4,000 shares and bought $9,999 worth of shares (3,636 units at $2.75), decreasing direct ownership by 0.08% to 471,456 units (SEC Form 4)

    4 - NEXGEL, INC. (0001468929) (Issuer)

    11/22/24 4:54:08 PM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    $NXGL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Maxim Group initiated coverage on NexGel with a new price target

    Maxim Group initiated coverage of NexGel with a rating of Buy and set a new price target of $6.00

    2/25/22 9:17:01 AM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    $NXGL
    Leadership Updates

    Live Leadership Updates

    View All

    NEXGEL Appoints Dave Hazard as Vice President of Sales for BIONX Surgical

    Appointment Supports Commercialization of Newly Launched BIONX Surgical Division, Formed Through Transformative Acquisition Expected to Significantly Scale Revenue LANGHORNE, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the appointment of Dave Hazard as Vice President of Sales for BIONX Surgical, a division of NEXGEL. Mr. Hazard brings more than 13 years of sales leadership across orthopedics, spine, and biologics, and joins BIONX Surgical at a

    5/13/26 8:30:00 AM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    NEXGEL Appoints Brian Kieser and Kevin Harris from New Strategic Partner, Sequence LifeScience™, to Board of Directors

    Sequence LifeScienceTM Led Financing to Close on Acquisition of Celularity with Strategic Investment of $5.5 Million LANGHORNE, Pa., May 06, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the appointment of Brian J. Kieser, CPA, and Kevin Harris, CFA, to the Board of Directors. Mr. Kieser is currently the CEO and Mr. Harris is the COO of Sequence LifeScienceTM, which recently led the financing to close on the acquisition of Celularity Inc.'s degenerative dise

    5/6/26 9:00:00 AM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    NEXGEL Appoints Ian Blackman as Chief Financial Officer

    Veteran Financial and M&A Leader Appointed to Integrate Acquisition of Celularity, Scale the Business and Accelerate Growth LANGHORNE, Pa., April 27, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the appointment of Ian Blackman, CPA, as Chief Financial Officer. Mr. Blackman will help to advance the closing of the definitive agreement to license and acquire a portfolio of commercial-stage regenerative biomaterial products from Celularity Inc., ("Celularity")

    4/27/26 9:00:00 AM ET
    $CELU
    $NXGL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    $NXGL
    Financials

    Live finance-specific insights

    View All

    NEXGEL To Report First Quarter 2026 Financial Results on May 15th

    Management Will Host a Conference Call at 12:00 P.M. ET on the Same Day LANGHORNE, Pa., May 12, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced it will report its financial results for the first quarter 2026 ended March 31, 2026, on Friday, May 15, 2026. Following the release of its financial results, the Company will host a conference call at 12:00 P.M. ET on the same day. First Quarter 2026 Financial Results Conference Call:Date: May 15, 2026Time: 12:00 P.M

    5/12/26 10:27:00 AM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    NEXGEL Moves Forward Shareholder Update Call to Discuss Celularity Transaction on April 21st at 4:30 P.M. ET

    LANGHORNE, Pa., April 17, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced it is moving up its shareholder update conference call from Thursday, April 23rd to Tuesday, April 21st, 2026, at 4:30 P.M. ET. Shareholder Update Call Details:Date: April 21, 2026Time: 4:30 P.M. ETLive Call: 1-800-267-6316 (U.S. Toll Free) or 1-203-518-9783 (International)Webcast: Events and Presentations About NEXGEL, Inc.NEXGEL is a leading provider of healthcare, beauty, and over-th

    4/17/26 3:37:00 PM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    NEXGEL Reschedules Shareholder Update Conference Call to April 23rd at 4:30 P.M. ET to Provide Update on Celularity Transaction

    LANGHORNE, Pa., April 15, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the rescheduling of its shareholder update conference call to April 23, 2026, at 4:30 P.M. ET. While there is no assurance that the Celularity transaction will close, the Company will not be financing the transaction under its previously announced Securities Purchase Agreement with a certain institutional investor. The Company is in the process of negotiating a new agreement with a diffe

    4/15/26 4:12:00 PM ET
    $NXGL
    Medical/Dental Instruments
    Health Care